Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients

Journal of the Indian Medical Association

Volumn 107, Issue 3, 2009, Pages 178-182

  Vijan, Suresh G ^a,b  

^a LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

^b Wockhardt Hospitals India   (India)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Cardiovascular diseases; Heart failure; Hypertension; Ramipril

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; INDUCED HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SIDE EFFECT; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT INDICATION;

EID: 77957663006     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gupta R, Rastogi P, Gupta VP - Correlation of cardiovascular mortality with nutritional and lifestyle factors in India: National Family Health Survey-2 and Indian Nutrition Profile Study. Indian Heart J 2004; 56: 474.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al - Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
3. Amman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al - ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 671-719.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al - ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: 1116-43.
5. JNC 7 - Seventh Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-72.
6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al - Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
7. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al - Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.
8. Ambrosioni E, Borghi C, Magnani B - The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80-5.
9. Francis, Gary S - ACE inhibition in cardiovascular disease. N Engl J Med 2000; 342: 201-2.
10. Wienbergen H, Schiele R, Gitt AK, Juenger C, Heer T, Meisenzahl C, et al - MITRA PLUS Study Group. Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol 2002; 90: 1045-9. (Pubitemid 35335591)
11. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, et al - Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
12. Kleinert S - HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. The Heart Outcomes Prevention Evaluation. Lancet 1999; 354: 841.
13. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al - Use of ramipril in preventing stroke: double blind randomised trial; the HOPE Investigators. BMJ 2002; 324: 699-702.
14. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators - Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
15. Schrader J, Lüders S, Züchner C, Herbold M, Schrandt G - Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study): a randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment. J Hum Hypertens 2000; 14: 435-40. (Pubitemid 30461930)
16. Brandt D - Treatment of arterial hypertension with ramipril: results of the austrian ramipril trial (ART I) - an open multicentre general practice study. Clin Drug Invest 1996; 12: 8-15.
17. Nielsen FS, Sato A, Ali S, Tarnow L, Smidt UM, Kastrup J, et al - Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. Diabetes Care 1998; 21: 804-9.
18. Eichstaedt H, Danne O, Langer M, Cordes M, Schubert C, Felix R, et al - Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging. J Cardiovasc Pharmacol 1989; 13: S75-S80. (Pubitemid 19172494)
19. Andersson F, Cline C, Rydén-Bergsten T, Erhardt L - Angiotensin converting enzyme (ACE) inhibitors and heart failure. Pharmacoeconomics 1999; 15: 535-50.
20. McMurray JJV - Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998; 19: L15-21
21. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al - Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
22. Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, et al - Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study-ELITE II. J Card Fail 1999; 5: 146-54. (Pubitemid 29297807)
23. Dickstein K, Kjekshus J - Effects of losartan and captopril on mortality and morbidity in high - risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-60.
24. Jong P, Demers C, McKelvie RS, Liu PP - Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002; 39: 463-70.
25. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al - Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61. (Pubitemid 39447136)
26. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC - Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828.
27. Cohn JN, Tognoni G - Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
28. Cayley WE Jr - Valsartan in chronic heart failure. N Engl J Med 2002; 346: 1173-4.
29. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al - Effects of candesartan in patients with chronic heart failure and reduced left-ventricular, systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71 (Pubitemid 37093916)
30. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al - for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
31. World Medical Association - The Declaration of Helsinki (Doc 17.c). 2002.
32. World Medical Association - Declaration of Helsinki : recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-6.
33. Committee for Proprietary Medicinal Products (CPMP) - Points to consider on switching between superiority and non-inferiority. London: EMEA, 2000.
34. Kaul S, Diamond GA - "Good enough: a primer on the analysis and interpretation of noninferiority trials". Ann Intern Med 2006; 145: 62-9.
35. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al - European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
36. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association - Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 705-8.
37. American Diabetes Association - Standards of medical care in diabetes. Diabetes Care 2005; 28: S4-36.
38. American Diabetes Association - Standards of medical care in diabetes-2008. Diabetes Care 2008; 31: S12-S54.